Melphalan-Flufenamide (Melflufen)

Phase 2Small molecule

Melphalan-Flufenamide (Melflufen) is one of 69 small molecule programs targeting Amyloidosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AmyloidosisActive, not recruiting

Multiple MyelomaActive, not recruiting

AmyloidosisPhase 1

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Nolvadex

AstraZeneca

Preclinical

1 7

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 8

Intron a

Merck & Co.

Preclinical

—9

Melphalan-Flufenamide (Melflufen)

OOncopeptides AB

Phase 2

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Amyloidosis1 trial

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Terminated·OOncopeptides AB·Phase 1·NCT04115956·6 enrolled

Daratumumab1 trial

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

Terminated·OOncopeptides AB·Phase 1/2·NCT03481556·56 enrolled

Multiple Myeloma1 trial

A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Completed·OOncopeptides AB·Phase 2·NCT02963493·157 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Melphalan-Flufenamide (Melflufen). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Melphalan-Flufenamide (Melflufen) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Melphalan-Flufenamide (Melflufen). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oncopeptides AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOncopeptides AB

Melphalan-Flufenamide (Melflufen)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Amyloidosis1 trial

Daratumumab1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News